Immix Biopharma, Inc. (IMMX)
NASDAQ: IMMX · Real-Time Price · USD
1.660
-0.040 (-2.35%)
Mar 31, 2025, 2:30 PM EDT - Market open
Immix Biopharma Employees
As of December 31, 2023, Immix Biopharma had 17 total employees, including 14 full-time and 3 part-time employees. The number of employees increased by 6 or 54.55% compared to the previous year.
Employees
17
Change (1Y)
6
Growth (1Y)
54.55%
Revenue / Employee
n/a
Profits / Employee
-$1,271,375
Market Cap
46.02M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 17 | 6 | 54.55% |
Dec 31, 2022 | 11 | 9 | 450.00% |
Dec 31, 2021 | 2 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
IMMX News
- 7 weeks ago - Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis - GlobeNewsWire
- 2 months ago - Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T - GlobeNewsWire
- 3 months ago - Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis - GlobeNewsWire
- 3 months ago - Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis - GlobeNewsWire
- 3 months ago - Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024 - GlobeNewsWire
- 4 months ago - Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media - GlobeNewsWire
- 4 months ago - Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients - GlobeNewsWire
- 6 months ago - Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2 - GlobeNewsWire